Thrivent Financial for Lutherans Acquires 2,688 Shares of DaVita Inc. (NYSE:DVA)

Thrivent Financial for Lutherans increased its holdings in DaVita Inc. (NYSE:DVA) by 49.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,131 shares of the company’s stock after acquiring an additional 2,688 shares during the quarter. Thrivent Financial for Lutherans’ holdings in DaVita were worth $1,333,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. Assenagon Asset Management S.A. increased its stake in shares of DaVita by 29.6% during the second quarter. Assenagon Asset Management S.A. now owns 50,096 shares of the company’s stock valued at $6,942,000 after purchasing an additional 11,454 shares in the last quarter. Comerica Bank raised its stake in DaVita by 41.4% during the first quarter. Comerica Bank now owns 34,431 shares of the company’s stock valued at $4,753,000 after buying an additional 10,074 shares during the last quarter. MBB Public Markets I LLC bought a new stake in DaVita in the second quarter worth $582,000. Chase Investment Counsel Corp grew its stake in shares of DaVita by 56.3% in the third quarter. Chase Investment Counsel Corp now owns 33,084 shares of the company’s stock worth $5,423,000 after acquiring an additional 11,912 shares during the last quarter. Finally, Promethos Capital LLC increased its holdings in shares of DaVita by 120.0% during the second quarter. Promethos Capital LLC now owns 28,396 shares of the company’s stock valued at $3,935,000 after acquiring an additional 15,490 shares in the last quarter. 90.12% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. UBS Group upped their price target on shares of DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. Truist Financial raised their price target on shares of DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research report on Monday, October 7th. Bank of America upped their price objective on DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research report on Wednesday, August 7th. Finally, Barclays lifted their target price on DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $161.80.

Insider Buying and Selling at DaVita

In related news, CEO Javier Rodriguez sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the completion of the sale, the chief executive officer now directly owns 837,835 shares in the company, valued at approximately $138,284,666.75. The trade was a 5.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 2.00% of the stock is owned by corporate insiders.

DaVita Stock Up 0.3 %

DVA opened at $166.17 on Friday. DaVita Inc. has a twelve month low of $99.18 and a twelve month high of $169.51. The company has a quick ratio of 1.33, a current ratio of 1.37 and a debt-to-equity ratio of 15.78. The firm has a 50 day moving average price of $158.57 and a 200-day moving average price of $149.31. The stock has a market capitalization of $13.63 billion, a price-to-earnings ratio of 17.93, a PEG ratio of 0.93 and a beta of 0.89.

DaVita (NYSE:DVA) last announced its earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). The company had revenue of $3.26 billion for the quarter, compared to analysts’ expectations of $3.25 billion. DaVita had a net margin of 6.53% and a return on equity of 88.18%. DaVita’s quarterly revenue was up 4.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.85 earnings per share. Equities research analysts forecast that DaVita Inc. will post 9.71 earnings per share for the current year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.